Camilla Kappe
Overview
Explore the profile of Camilla Kappe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuhre R, Holst J, Kappe C
Clin Sci (Lond)
. 2015 Dec;
130(2):79-91.
PMID: 26637406
Glucagon-like peptide-1 (GLP-1) is a peptide hormone, released from intestinal L-cells in response to hormonal, neural and nutrient stimuli. In addition to potentiation of meal-stimulated insulin secretion, GLP-1 signalling exerts...
2.
Fred R, Kappe C, Ameur A, Cen J, Bergsten P, Ravassard P, et al.
Mol Cell Endocrinol
. 2015 Jul;
414:53-63.
PMID: 26213325
The aim of the present investigation was to delineate cytokine-induced signaling and death using the EndoC-βH1 cells as a model for primary human beta-cells. The cytokines IL-1β and IFN-γ induced...
3.
Kappe C, Fransson L, Wolbert P, Ortsater H
Clin Sci (Lond)
. 2015 Apr;
129(5):405-14.
PMID: 25853863
Evidence indicates that subtle abnormalities in GC (glucocorticoid) plasma concentrations and/or in tissue sensitivity to GCs are important in the metabolic syndrome, and it is generally agreed that GCs induce...
4.
Kappe C, Zhang Q, Nystrom T, Sjoholm A
Diabetol Metab Syndr
. 2014 Jul;
6:70.
PMID: 25028601
Background: Elevated serum free fatty acids (FFAs) contribute to the pathogenesis of type-2-diabetes (T2D), and lipotoxicity is observed in many cell types. We recently showed that simulated hyperlipidemia induces lipoapoptosis...
5.
Kappe C, Zhang Q, Holst J, Nystrom T, Sjoholm A
Am J Physiol Cell Physiol
. 2013 Aug;
305(10):C1041-9.
PMID: 23986202
Glucagon-like peptide-1 (GLP-1), secreted from gut L cells upon nutrient intake, forms the basis for novel drugs against type 2 diabetes (T2D). Secretion of GLP-1 has been suggested to be...
6.
Kappe C, Tracy L, Patrone C, Iverfeldt K, Sjoholm A
J Neuroinflammation
. 2012 Dec;
9:276.
PMID: 23259618
Background: Type 2 diabetes (T2D) is a strong risk factor for developing neurodegenerative pathologies. T2D patients have a deficiency in the intestinal incretin hormone GLP-1, which has been shown to...
7.
Kappe C, Holst J, Zhang Q, Sjoholm A
Biochem Biophys Res Commun
. 2012 Sep;
427(1):91-5.
PMID: 22982676
Background: Evidence is emerging that elevated serum free fatty acids (hyperlipidemia) contribute to the pathogenesis of type-2-diabetes, and lipotoxicity is observed in many cell types. We recently published data indicating...
8.
Kappe C, Patrone C, Holst J, Zhang Q, Sjoholm A
J Gastroenterol
. 2012 Aug;
48(3):322-32.
PMID: 22850868
Background: Metformin is the most frequently prescribed drug for treatment of type 2 diabetes. It improves insulin resistance and glycemia by reducing hepatic gluconeogenesis. In addition, diabetic patients on metformin...
9.
Wu L, Olverling A, Fransson L, Ortsater H, Kappe C, Gao X, et al.
Regul Pept
. 2012 May;
177(1-3):92-6.
PMID: 22587909
Liraglutide, an analog of glucagon-like peptide-1 (GLP-1), is an effective anti-diabetic agent with few side effects. Since native GLP-1 exerts vascular effects, we investigated changes in pancreatic islet blood flow...
10.
Darsalia V, Mansouri S, Ortsater H, Olverling A, Nozadze N, Kappe C, et al.
Clin Sci (Lond)
. 2011 Dec;
122(10):473-83.
PMID: 22150224
Diabetes is a strong risk factor for premature and severe stroke. The GLP-1R (glucagon-like peptide-1 receptor) agonist Ex-4 (exendin-4) is a drug for the treatment of T2D (Type 2 diabetes)...